Q-omics provides the consensus-scored MAP3K6 profile across patient tissues and cancer cell-line models. MAP3K6 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, MAP3K6 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, MAP3K6 protein abundance shows 19,454 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, THCA, and GBM as cancer lineages where MAP3K6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP3K6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP3K6 survival associations across molecular data types. MAP3K6 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP3K6 RNA expression–survival associations across cancer types. High MAP3K6 expression shows unfavorable associations in LGG, MESO, UCS and LAML, but favorable associations in HNSC and THCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for MAP3K6 RNA expression.
This table summarizes MAP3K6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAP3K6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP3K6 shows lower tumor expression in BRCA and LUAD and higher tumor expression in THCA, KIRC, LIHC and PAAD. The THCA box plot shows higher MAP3K6 RNA expression in tumor versus normal tissue (log2 FC = +1.154, t-test p < 0.001).
This table shows molecular features associated with MAP3K6 in patient tissues and cancer cell lines. In patient samples, MAP3K6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP3K6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
